HMGB1和ENA-78在突发性耳聋患者治疗前后的变化

Different Level of HMGB1 and ENA-78 before and after the Treatment of Patients with Sudden Deafness

目的:探寻两种炎症介质血清高迁移率蛋白-1(HMGB1)以及中性粒细胞激活肽-78(ENA-78)在特发性突发性聋患者体内随病情变化的不同,及其这两种物质对该病患者的机体影响和所发挥的作用。方法:采用双抗夹心包板、免疫的方法(ELISA)来检测受试者体内中血清HMGB1和ENA-78的含量,受试者包括114例确诊的突发性耳聋患者(分为低度,中度和重度),38例其他疾病对照患者和36例正常健康的成年对照者。并观察这两种物质在患者治疗前后浓度上所产生的不同。结果:患有特发性突发性聋的患者按本文方案治疗后体内的HMGB1和ENA-78含量比治疗前降低显著,且患病程度越重的被测者血清中HMGB1和ENA-78的浓度越大,有正向关系;患有突发性耳聋的受试者两种被测物的含量高于患有其他疾病及健康的对照者,具有统计学意义(P<0.01)。结论:对于患有特发性突发性聋的患者,HMGB1和ENA-78在体内血清中的浓度可以作为诊断和患者患病程度的检测标准参考。

Objective：To explore two inflammatory of high mobility group box-1 protein（HMGB1） and neutrophilactivating peptide the-78（ENA-78） in the dynamic changes of patients with sudden deafness,and the effect of the two substances to the patient’s body.Methods：The levels of HMGB1 and ENA-78 were determined by double antibody sandwich enzyme-linked immunosorbent assay（ELISA） method in the 114 diagnosed patients with sudden deafness（divided into low,moderate and severe）,38 cases of other disease control patients and 36 patients who are healthy adult controls.Observe the differences between these two substances’ concentration before and after the treatment of sudden deafness patients.Results：Levels of HMGB1 and ENA-78 in patients suffering from idiopathic sudden deafness were decreased after the treatment by this program significantly,therefore these two substances,the more,the patients more serious.with positive realationship.Levels of HMGB1 and ENA-78 in patients suffering from sudden deafness were higher than people with other diseases and healthy controls,a statistically significant（P＆lt;0.01）.Conclusion：For the patients with sudden hearing loss,levels of HMGB1 and ENA-78 in the serum can be regarded as a standard reference of diagnosition and diseases condition.